ABSTRACT
This chapter lists the most used immunophenotypic markers in the diagnosis of hematological neoplasms. In the past years, however, determination of the cell surface markers of tumors gained another very important role, becoming the basis for targeted therapies with monoclonal antibodies directed against the surface molecules, the best-known example being rituximab for CD20+ lymphomas. Table 4.1 lists the most common examples of antibodies used currently in targeted therapies.
